Drug intelligence / Profile preview

roconkibart

Development stage: Phase 3
Lead developer: Junshi Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Injection

Overview

Roconkibart is a novel therapeutic agent, currently under investigation as a monoclonal antibody primarily targeted at oncology and immunology. It is designed to specifically target and bind to certain proteins or receptors implicated in disease processes. In oncology, it aims to inhibit the growth and proliferation of cancer cells and mark them for destruction by the immune system. In immunology, it modulates immune responses by targeting specific cytokines or immune checkpoints. Clinical trials are advancing, with Phase III trials underway for its potential use in advanced or metastatic cancers and other immunological conditions.

Other names: ruokaocibai mAb偌考奇拜单抗recombinant humanized anti-IL-17A monoclonal antibody

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on roconkibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on roconkibart.

Explore the full profile